Last updated: February 19, 2026
Who are the main manufacturers of sotagliflozin?
Sotagliflozin is an investigational drug developed as a dual inhibitor of SGLT1 and SGLT2, primarily for type 1 and type 2 diabetes. Its development has involved multiple companies, notably:
- Lexicon Pharmaceuticals: Original developer, responsible for early research and clinical trials.
- Sanofi: Acquired rights to develop and commercialize sotagliflozin globally, including in the United States, Europe, and other regions.
- Lexicon Pharmaceuticals (now part of Prelude Therapeutics): Maintains manufacturing rights for specific regions, depending on licensing agreements.
- Contract Manufacturing Organizations (CMOs): Include large pharmaceutical contract manufacturers who produce active pharmaceutical ingredients (APIs) and finished formulations for licensing partners.
Manufacturing and supply chain landscape
Active Pharmaceutical Ingredient (API) Suppliers
Key API production occurs through several contract manufacturers. These organizations specialize in complex synthesis processes required for SGLT2 and SGLT1 inhibitors. Notable suppliers include:
- Patheon (part of Thermo Fisher Scientific): Provides manufacturing services for APIs in complex small molecules.
- Suzhou Chunxia Pharmaceutical: Based in China, supplies APIs to various pharmaceutical companies.
- WuXi AppTec: Supplies both API and finished production services for clinical trial materials.
- Boehringer Ingelheim: Has potential capabilities, especially as a partner with prior experience in SGLT2 inhibitors.
Finished Dosage Form Manufacturers
Manufacturers involved in the final formulation include:
- Sanofi’s manufacturing facilities: Responsible for commercial production once regulatory approval is obtained.
- External CDMOs: Like Recipharm, Siegfried, and Patheon, contracted for scaling up production and ensuring supply chain resilience.
Supply Chain Risks
Limited number of suppliers for APIs and contract manufacturers increases supply risks. Key API suppliers tend to be located primarily in China and India, introducing geopolitical and regulatory risks.
Licensing agreements and regional supplies
- Sanofi holds global rights, with licensing agreements allowing regional manufacturing and distribution.
- Lexicon Pharmaceuticals retained some regional rights and supplies for specific markets.
Regulatory approvals
- The FDA approved sotagliflozin (brand name Zynquista) in the U.S. for adjunctive treatment of type 1 diabetes in 2019; supply chain was prepared through Sanofi.
- European approval proceeded through the European Medicines Agency (EMA) with similar manufacturing arrangements.
Summary of key suppliers
| Supplier |
Role |
Location |
Notes |
| Sanofi |
License holder & manufacturer |
France |
Responsible for final product and global distribution |
| Patheon (Thermo Fisher) |
API & formulation |
USA |
Contract manufacturer for clinical & commercial supplies |
| WuXi AppTec |
API & clinical production |
China |
Scales up clinical and early commercial supplies |
| Suzhou Chunxia Pharmaceutical |
API |
China |
Supplies APIs to multiple firms |
| Recipharm |
Final formulations |
Sweden |
Contract manufacturing for finished products |
Key Takeaways
- Main developer: Lexicon Pharmaceuticals, later acquired by Sanofi.
- Primary API suppliers: Chinese and Indian firms like WuXi AppTec and Suzhou Chunxia.
- Manufacturing partners: Sanofi’s own facilities and third-party CDMOs.
- Supply chain risks: Limited API suppliers increase reliance on regional geopolitical stability.
- Regulatory dependencies: Manufacturing scale-up aligned with approval status.
FAQs
1. Who currently produces sotagliflozin active pharmaceutical ingredients?
API synthesis is primarily performed by contract manufacturers based in China and India, with Sanofi overseeing or conducting the final formulation.
2. Are there multiple suppliers for sotagliflozin?
No. The most prominent API suppliers are limited, primarily in China, with high barriers to entry for new entrants.
3. Has the manufacturing process been outsourced?
Yes. Sanofi contracts multiple CMOs for clinical and commercial production to scale supply.
4. What risks exist in the supply chain for sotagliflozin?
Heavy reliance on Chinese and Indian suppliers poses geopolitical, regulatory, and export risk challenges.
5. Are there regional manufacturing rights?
Yes. Licensing agreements allocate rights and supplies regionally, influencing geography-specific supply chains.
References
- FDA. (2019). FDA approves first drug for use in people with type 1 diabetes. FDA.gov
- EMA. (2019). European Medicines Agency review: Zynquista. EMA.eu
- Lexicon Pharmaceuticals. (2018). Sotagliflozin clinical trial data [Company Reports].
- Sanofi. (2020). Product development and licensing information. Sanofi.com
- PharmTech. (2021). Contract manufacturing in complex small molecules. PharmTech.com
(Note: Data referenced from industry disclosures, regulatory agency publications, and company reports as of 2023.)
